Challenges and opportunities with plasma-derived therapies

For the newest pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Dr Kristina Allikmets, SVP and head of R&D at Takeda’s plasma-derived therapies business unit.

Plasma-derived therapies present unique life-saving opportunities for people with rare and complex diseases, but their main ingredient, blood plasma, can’t be synthesised with current technology. Instead, it has to be sourced from donors, requiring a significant infrastructure.

Dr Allikmets discusses how this all works at Takeda, how they make sure patients always have access to the therapies they need, and other ways they’re innovating in the space.

You can listen to episode 81 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Stitcher, and Podbean.